Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.99Last Year’s EPS
-1.8Same Quarter Last Year
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 11, 2025
|% Change Since: -0.56%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects positive momentum with the successful launch and strong adoption of ZURZUVAE in the market, supported by effective commercial strategies and comprehensive coverage. However, challenges remain with revenue growth not keeping pace with demand and significant net losses impacting financial health.Company Guidance
During Sage Therapeutics' fourth quarter and full year 2024 financial results conference call, the company outlined its strategic priorities for 2025, emphasizing the commercial success of ZURZUVAE for postpartum depression (PPD). Key metrics included over 6,600 prescriptions shipped in 2024, with a 21% increase in Q4 alone. The company reported $11.4 million in Q4 collaboration revenue from ZURZUVAE sales, contributing to a total of $36.1 million for the year. Notably, OBGYNs accounted for nearly 80% of prescriptions, with 70% of patients receiving ZURZUVAE as their first treatment for PPD. Sage also highlighted its financial position, with cash reserves projected to support operations until mid-2027, and plans to expand its sales force and enhance media investments to drive ZURZUVAE's market penetration further.Successful Launch of ZURZUVAE
ZURZUVAE, the first and only oral treatment for postpartum depression (PPD), surpassed initial expectations with over 6,600 prescriptions shipped in 2024, indicating strong market demand and adoption among healthcare providers.
Commercial Coverage and Access
Greater than 95% of commercial and Medicaid lives are covered, with most having no step edits or complex prior authorizations, reflecting strong payer recognition of ZURZUVAE's value.
Salesforce Expansion and Market Penetration
The salesforce expansion led to a 33% growth in patient shipments in targeted territories, highlighting the market's responsiveness to promotional efforts.
Financial Position and Cash Runway
The company reported a cash runway expected to last until mid-2027, supported by existing cash, anticipated collaboration funding, and projected revenues.
---
SAGE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SAGE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 11, 2025 | $7.19 | $7.16 | -0.42% |
| Oct 29, 2024 | $8.48 | $6.44 | -24.06% |
| Jul 31, 2024 | $10.80 | $10.95 | +1.39% |
| Apr 25, 2024 | $14.00 | $13.58 | -3.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does SAGE Therapeutics (SAGE) report earnings?
SAGE Therapeutics (SAGE) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is SAGE Therapeutics (SAGE) earnings time?
SAGE Therapeutics (SAGE) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SAGE EPS forecast?
SAGE EPS forecast for the fiscal quarter 2025 (Q1) is -0.99.
---
